Skip to content

Safety and effectiveness evaluation of Huvitz’s corneal topographer HTG-1

Safety and effectiveness evaluation of Huvitz’s corneal topographer HTG-1

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0011307
Enrollment
80
Registered
2025-12-11
Start date
2025-11-03
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Huvitz
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Normal eye (1) Adults aged 19 to 80 years (2) Those who can follow medical staff's instructions during clinical trials (3) Those who have given written consent to participate in clinical trials 2) Dry eye disease (DED) (1) Includes the selection criteria for normal eyes (1, 2, 3) (2) Eyes diagnosed with dry eye disease

Exclusion criteria

Exclusion criteria: (1) Eyes with light reflection from the cornea, insufficient eye opening, or misaligned eyelashes that make measurement difficult. (2) Eyes that cannot fixate their gaze, which may affect image acquisition and measurement values. (3) Eyes that have worn hard contact lenses within the past two weeks or soft contact lenses within the past two hours. (4) Eyes with keratoconus. (5) Eyes with a history of ophthalmic surgery for corneal or retinal diseases, including laser treatment/surgery or refractive surgery. (6) Eyes with corneal diseases such as corneal opacity or overt keratitis. (7) Eyes with facial nerve paralysis. (8) Eyes deemed unsuitable by the researcher.

Design outcomes

Secondary

MeasureTime frame
Agreement of dry eye inspection;Keratometry and dry eye inspection differences between normal eye and dry eye groups.;Topo map repeatability;safety

Primary

MeasureTime frame
Keratometry repeatability and agreement

Countries

Korea, Republic of

Contacts

Public ContactEom Ye Ji

The Catholic University of Korea, Bucheon St. Mary's Hospital

eyj0726@gmail.ocm+82-31-340-2847

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026